Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

China Feature Special

- PMLiVE

What about me? Human centricity rather than patient centricity…

While the pace of change within the digital transformation brings both benefits and challenges, are HCPs being left behind?

Porterhouse Medical Group

- PMLiVE

FDA looks to regulate digital tools

US regulator adds new components to digital health plan

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

AstraZeneca AZ

AZ’s immuno-oncology combo fails another lung cancer trial

Latest failure casts doubt on company’s CTLA4 drug

- PMLiVE

AZ makes case for first-line Tagrisso therapy in lung cancer

Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva

- PMLiVE

AZ taps Ionis for another drug, this time in NASH

Will acquire the US pharma group’s antisense drug in a deal valued up to $330m

- PMLiVE

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Both EU and US regulatory advisors are currently assessing the drug

- PMLiVE

AZ finally gets EU nod for Veltassa rival Lokelma

And expects a US FDA verdict for the hyperkalaemia treatment later this year

- PMLiVE

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

The studies will look at the vaccines in combination with chemotherapy

AstraZeneca AZ

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

Studies show that the drug reduced risk of disease progression

AstraZeneca AZ

AZ bags key lung cancer approval for Imfinzi

Becomes the first PD-1/PD-L1 inhibitor approved to treat inoperable stage III NSCLC patients

- PMLiVE

AZ expects return to growth this year after 2017 decline

Soriot says the pharma company is 'turning a corner'

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links